Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology · Hypereosinophilic Syndrome

Blood Clots and Platelets: Navigating the Risks

At a Glance

High eosinophil levels can make blood more likely to clot by damaging blood vessels and activating clotting. Platelets may be high or low, so doctors must treat the underlying eosinophilia while balancing clot risk against bleeding risk.

When your eosinophil counts are high, your blood chemistry changes in a way that makes it significantly more likely to form blood clots—a state doctors call being hypercoagulable. This risk is one of the most serious aspects of hypereosinophilia, as it can lead to complications like deep vein thrombosis (DVT), pulmonary embolism (PE), or even stroke [1][2].

Understanding the complex relationship between eosinophils and your platelets is key to managing this risk.

The High Risk of Blood Clots

Research shows that the risk of a blood clot (thrombosis) is remarkably high in some patients with Hypereosinophilic Syndrome (HES).

  • Incidence: In one study of a specific cohort of patients with HES, about 24% (nearly 1 in 4) experienced at least one blood clot, either in their veins or their arteries [1]. These figures are cohort-specific observations and should not be used as an individual risk estimate for reactive eosinophilia.
  • Location: Among those who develop clots in these studies, more than half (52%) may experience a pulmonary embolism (a clot in the lungs), while 37% develop a DVT in the legs [2].
  • Persistence is Key: The longer your eosinophil counts stay high, the higher your risk. One cohort study found that having hypereosinophilia for more than 13.9 months was associated with a higher risk for lung clots [3]. Furthermore, if eosinophils aren’t brought under control, the time it takes for a second clot to form is much shorter [2].

Why Eosinophils Cause Clots

Eosinophils do not just “crowd” the blood; they actively promote clotting through several biological mechanisms:

  1. Granule Release: The toxic proteins released by eosinophils can damage the endothelium (the lining of your blood vessels). A damaged lining is a surface that invites clots to form [4][5].
  2. Heart Involvement: In the heart, eosinophils can cause inflammation that leads to mural thrombi—large clots that form against the inner walls of the heart [6][7]. These clots can break loose and travel to the brain, causing a stroke [8].
  3. Procoagulant Activity: Eosinophils release substances that directly activate the clotting system, increasing the tendency for clot formation [9].

The Platelet Connection: Highs and Lows

Your platelet count—whether it is too high or too low—provides vital clues about what is happening in your body.

Thrombocytosis (High Platelets)

High platelets are often a reactive response to the same inflammation driving your eosinophils. When your body is inflamed, it releases a messenger called Interleukin-6 (IL-6), which tells the liver and bone marrow to produce more platelets [10]. However, if your platelets remain high and your marrow looks abnormal, it may signal a myeloproliferative neoplasm (MPN)—a condition where the bone marrow is overproducing cells due to a genetic mutation [11].

Thrombocytopenia (Low Platelets)

It may seem contradictory, but you can have a high risk of blood clots even when your platelet count is low. This can sometimes happen through platelet consumption. When your body is forming many clots (as seen in severe HES or a complication called DIC or TMA), it can “use up” its supply of platelets faster than it can replace them [12][13]. However, a low platelet count is not presumed to be consumption; it must prompt prompt clinical evaluation for other causes like immune destruction, medications, or marrow failure, as well as an assessment of bleeding risk [14].

Managing the Balance

Treating blood clots in this setting is a delicate balancing act.

  • Anticoagulation: Doctors use “blood thinners” (anticoagulants) to treat and prevent clots. Common choices include Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulants (DOACs) [15].
  • The Bleeding Risk: If your platelets are very low, the risk of bleeding increases. Doctors must carefully weigh the risk of a new clot against the risk of a dangerous bleed [16].
  • Safety Instruction: Do not start, stop, or alter an anticoagulant without the explicit guidance of your treating team. Seek urgent advice for any significant bleeding.
  • Targeting the Root Cause: The most important way to reduce your risk of a future clot is to lower your eosinophil count. This is typically done with corticosteroids or targeted therapies like mepolizumab or imatinib, depending on your specific diagnosis [17][18].

Lowering your eosinophil count doesn’t just improve your “numbers”; it directly addresses the underlying mechanisms driving the clotting process [2].

Common questions in this guide

Why can high eosinophil levels cause blood clots?
Eosinophils can release proteins that injure the lining of blood vessels and substances that activate clotting. In the heart, inflammation can also contribute to clots attached to the heart wall that may travel to the brain.
Can I develop a blood clot if my platelet count is low?
Yes. In severe disease, platelets can be used up while many clots are forming, but low platelets can also result from immune destruction, medicines, or bone marrow problems. A low count increases bleeding risk and needs prompt clinical evaluation.
What symptoms of a blood clot need urgent medical attention?
Sudden leg swelling can signal a clot in a deep vein, while sudden shortness of breath may indicate a clot in the lungs. A severe or unusual headache may be a warning of a serious complication such as a stroke, so seek urgent medical attention for these symptoms.
How are blood clots treated when I have HES?
Clinicians may use blood thinners such as low molecular weight heparin or direct oral anticoagulants, but the choice and dose depend on both clotting and bleeding risk. Do not start, stop, or change an anticoagulant without guidance from your treating team.
How does treating eosinophilia reduce the chance of another clot?
Lowering the eosinophil count targets the processes that promote clotting, rather than only changing a laboratory number. Depending on the diagnosis, clinicians may use corticosteroids or targeted treatments such as mepolizumab or imatinib.
What can high platelets mean when eosinophil levels are high?
Inflammation can raise platelet production through the messenger interleukin-6, so a high count may be a reactive change. If platelets remain high and the bone marrow looks abnormal, clinicians may evaluate for a myeloproliferative neoplasm, in which the marrow overproduces blood cells.
What might cause low platelets during hypereosinophilia?
Low platelets can reflect consumption during severe clotting, but they are not automatically caused by consumption. Immune destruction, medications, and bone marrow failure are other possibilities, so a clinician must evaluate the cause and bleeding risk.

Get notified when new evidence is published on platelet abnormalities with eosinophilia and immune-mediated inflammatory disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations.

    Leiva O, Baker O, Jenkins A, et al.

    JAMA network open 2021; (4(8)):e2119812 doi:10.1001/jamanetworkopen.2021.19812.

    PMID: 34357393
  2. 2

    Venous thrombosis and predictors of relapse in eosinophil-related diseases.

    Réau V, Vallée A, Terrier B, et al.

    Scientific reports 2021; (11(1)):6388 doi:10.1038/s41598-021-85852-9.

    PMID: 33737704
  3. 3

    Hypereosinophilia with Concurrent Venous Thromboembolism: Clinical Features, Potential Risk Factors, and Short-term Outcomes in a Chinese Cohort.

    Liu Y, Meng X, Feng J, et al.

    Scientific reports 2020; (10(1)):8359 doi:10.1038/s41598-020-65128-4.

    PMID: 32433573
  4. 4

    Fulminant Idiopathic Hypereosinophilic Syndrome Presenting with Cardiac, Neurologic and Haematologic Involvement.

    Ibrahim N, Batri A, Rivera RR, Zwein A

    European journal of case reports in internal medicine 2025; (12(12)):006010 doi:10.12890/2025_006010.

    PMID: 41536447
  5. 5

    Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome.

    Torcida N, Casalino G, Bondue A, et al.

    Frontiers in cardiovascular medicine 2023; (10()):1256862 doi:10.3389/fcvm.2023.1256862.

    PMID: 37829688
  6. 6

    Eosinophilic myocarditis and hypereosinophilic syndrome.

    Boussir H, Ghalem A, Ismaili N, El Ouafi N

    Journal of the Saudi Heart Association 2017; (29(3)):211-213 doi:10.1016/j.jsha.2016.11.001.

    PMID: 28652675
  7. 7

    The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes.

    Reeder M, Okushi Y, Lo Presti Vega S, et al.

    Cardiovascular diagnosis and therapy 2024; (14(6)):1122-1133 doi:10.21037/cdt-24-347.

    PMID: 39790190
  8. 8

    Literature reviews of stroke with hypereosinophilic syndrome.

    Ono R, Iwahana T, Kato H, et al.

    International journal of cardiology. Heart & vasculature 2021; (37()):100915 doi:10.1016/j.ijcha.2021.100915.

    PMID: 34888412
  9. 9

    Persistent Hemorrhagic Lip Crusts as the Presenting Sign of Pediatric FIP1L1-PDGFRA-Positive Hypereosinophilic Syndrome: A Case Report and Review of the Literature.

    Chiang YK, Ho YH

    Pediatric dermatology 2026; (43(5)):1204-1208 doi:10.1111/pde.70233.

    PMID: 42014566
  10. 10

    Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.

    Kraakman MJ, Lee MK, Al-Sharea A, et al.

    The Journal of clinical investigation 2017; (127(6)):2133-2147.

    PMID: 28504650
  11. 11

    Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

    Wang SA, Hasserjian RP, Tam W, et al.

    Haematologica 2017; (102(8)):1352-1360 doi:10.3324/haematol.2017.165340.

    PMID: 28495918
  12. 12

    Rare Case of a Young Male Presented with Abdominal Pain, Solid Colon Tumors, and Eosinophilia, Followed by Tremendous Thromboembolic Complications and Eventually Diagnosed with Idiopathic Hypereosinophilic Syndrome.

    Zemleduch T, Czapla A, Kimla P, Kudliński B

    Case reports in medicine 2022; (2022()):1424749 doi:10.1155/2022/1424749.

    PMID: 35646123
  13. 13

    Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome.

    Chen TS, Xing LH, Wang SL, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(7)):831-834 doi:10.1097/MBC.0000000000000501.

    PMID: 26780165
  14. 14

    Pediatric hypereosinophilic syndrome associated with liver damage, portal vein, splenic vein and superior mesenteric vein thromboses: a case report.

    Zheng HT, Xu Y, Yan XY, et al.

    BMC pediatrics 2023; (23(1)):233 doi:10.1186/s12887-023-04014-0.

    PMID: 37173706
  15. 15

    2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

    Farge D, Frere C, Connors JM, et al.

    The Lancet. Oncology 2022; (23(7)):e334-e347 doi:10.1016/S1470-2045(22)00160-7.

    PMID: 35772465
  16. 16

    Thrombosis in the portal venous system caused by hypereosinophilic syndrome: A case report.

    Lin J, Huang X, Zhou W, et al.

    Medicine 2018; (97(48)):e13425 doi:10.1097/MD.0000000000013425.

    PMID: 30508952
  17. 17

    [Hypereosinophilic syndrome with first presentation of pulmonary embolism and extensive venous thrombosis: a case report and literature review].

    Xu W, Guo W, Yang T

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2015; (38(12)):912-7.

    PMID: 26850893
  18. 18

    Eosinophilic Myocarditis.

    Cheung CC, Constantine M, Ahmadi A, et al.

    The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

    PMID: 29173361

This page is for informational purposes only and does not constitute medical advice. It explains clotting and platelet issues in hypereosinophilia, but your hematology team should interpret your counts and guide any anticoagulant or eosinophil-lowering treatment.